Droxidopa Persistence in Neurogenic Orthostatic Hypotension May Be Affected by Titration Approach [PDF]
International Journal of General Medicine, 2021 Fahd Amjad,1 Brett Polenchar,2 Antonella Favit3 1Department of Neurology, Georgetown University Hospital Pasquerilla Healthcare Center, Washington, DC, USA; 2Business Insights, Lundbeck, Deerfield, IL, USA; 3Medical Affairs, Lundbeck, Deerfield, IL ...
Amjad F, Polenchar B, Favit A
doaj +2 more sources
Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment. [PDF]
Neurol Ther, 2022 Introduction Droxidopa is approved to treat neurogenic orthostatic hypotension (nOH) symptoms in patients with autonomic failure based on short-term clinical trial data. Additional data on the long-term efficacy of droxidopa are needed. We have evaluated
Hauser RA +6 more
europepmc +2 more sources
Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report [PDF]
Journal of Medical Case Reports, 2020 Background Droxidopa is an oral treatment for the stepwise treatment of neurogenic orthostatic hypotension from autonomic dysfunction. It has been shown to be useful predominantly with neurogenic orthostatic hypotension secondary to Parkinson’s disease ...
Annie H. Ho +4 more
doaj +2 more sources
Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial. [PDF]
Clin Auton Res, 2021 In neurogenic orthostatic hypotension, blood pressure falls when upright owing to impaired release of norepinephrine, leading to dizziness. Ampreloxetine, a selective norepinephrine reuptake inhibitor, increases circulating norepinephrine levels.
Kaufmann H +7 more
europepmc +2 more sources
Clinical management of neurogenic orthostatic hypotension
Annals of Movement Disorders, 2019 Neurogenic orthostatic hypotension is a common disorder often seen in elderly patients affected with neurodegenerative disorders and peripheral neuropathies.
Malligurki Raghurama Rukmani +3 more
doaj +2 more sources
An Unusual Case of Neurogenic Orthostatic Hypotension Without Parkinsonian Features
Annals of Internal Medicine: Clinical CasesOrthostatic hypotension is a common cause of syncope, especially in the older adult population. While it is a commonly encountered issue as a cause of syncope, neurogenic orthostatic hypotension (nOH) is less common.
Betul Gok Yavuz, Darian Fard, Asma Malik
doaj +2 more sources
Characterization of the changes in supine blood pressure with long‐term use of droxidopa in patients with neurogenic orthostatic hypotension [PDF]
Health Science Reports, 2021 Background and Aims Patients with neurogenic orthostatic hypotension (nOH) due to autonomic dysfunction may also experience supine hypertension (defined as supine systolic blood pressure [SBP] ≥140 mmHg).
L. Arthur Hewitt +5 more
doaj +2 more sources
Diagnosis and management of neurogenic orthostatic hypotension
Annals of Clinical Neurophysiology, 2023 Orthostatic hypotension is a sustained and pathological drop in blood pressure upon standing. Orthostatic hypotension can be due to non-neurogenic conditions or autonomic disorders.
Woohee Ju, Dong In Sinn
semanticscholar +2 more sources
A Call to Action: The Role of Healthcare Providers in Reducing the Burden Associated with Neurogenic Orthostatic Hypotension [PDF]
Neurology and Therapy, 2020 Plain Language Summary This article discusses what neurogenic orthostatic hypotension (nOH) is, its symptoms, and how patients and healthcare providers (HCPs) can work together to manage nOH symptoms. What is nOH?
Jessie S. Gibson +2 more
doaj +2 more sources
Carbon dioxide for neurogenic orthostatic hypotension in adults: a novel therapy. [PDF]
Eur Heart JBaker JR +7 more
europepmc +2 more sources